Does the CYP3A5*3 polymorphism affect in vivo drug elimination?THUMMEL, Kenneth E.Pharmacogenetics (London). 2003, Vol 13, Num 10, pp 585-587, issn 0960-314X, 3 p.Article

A genetic test for immunosuppressant dose selection?THUMMEL, Kenneth E.Pharmacogenetics (London). 2004, Vol 14, Num 3, pp 145-146, issn 0960-314X, 2 p.Article

First-pass drug metabolism and its impact on oral drug deliveryTHUMMEL, Kenneth E.Advanced drug delivery reviews. 1997, Vol 27, Num 2-3, issn 0169-409X, 162 p.Serial Issue

The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humansWILKINSON, G. R.Advanced drug delivery reviews. 1997, Vol 27, Num 2-3, pp 129-159, issn 0169-409XArticle

Adding pharmacogenetics information to drug labels: lessons learnedHAGA, Susanne B; THUMMEL, Kenneth E; BURKE, Wylie et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 12, pp 847-854, issn 1744-6872, 8 p.Article

Human immunodeficiency virus protease inhibitors : From drug design to clinical studiesLIN, J. H.Advanced drug delivery reviews. 1997, Vol 27, Num 2-3, pp 215-233, issn 0169-409XArticle

The barrier function of CYP3A4 and P-glycoprotein in the small bowelWATKINS, P. B.Advanced drug delivery reviews. 1997, Vol 27, Num 2-3, pp 161-170, issn 0169-409XArticle

Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug deliveryHEBERT, M. F.Advanced drug delivery reviews. 1997, Vol 27, Num 2-3, pp 201-214, issn 0169-409XArticle

Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction : Studies with Anti-Human Immunodeficiency Virus Protease InhibitorsGUPTA, Anshul; MUGUNDU, Ganesh M; DESAI, Pankaj B et al.Drug metabolism and disposition. 2008, Vol 36, Num 6, pp 1172-1180, issn 0090-9556, 9 p.Article

Stereochemical aspects of itraconazole metabolism in vitro and in vivoKUNZE, Kent L; NELSON, Wendel L; KHARASCH, Evan D et al.Drug metabolism and disposition. 2006, Vol 34, Num 4, pp 583-590, issn 0090-9556, 8 p.Article

Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugsMCCONN, Dnnavon J; LIN, Yvonne S; ALLEN, Kyle et al.Drug metabolism and disposition. 2004, Vol 32, Num 10, pp 1083-1091, issn 0090-9556, 9 p.Article

Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extractionTHUMMEL, K. E; KUNZE, K. L; SHEN, D. D et al.Advanced drug delivery reviews. 1997, Vol 27, Num 2-3, pp 99-127, issn 0169-409XArticle

Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophenDONG, Haijun; HAINING, Robert L; THUMMEL, Kenneth E et al.Drug metabolism and disposition. 2000, Vol 28, Num 12, pp 1397-1400, issn 0090-9556Article

Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugsFROMM, M. F; KROEMER, H. K; EICHELBAUM, M et al.Advanced drug delivery reviews. 1997, Vol 27, Num 2-3, pp 171-199, issn 0169-409XArticle

Selective induction of intestinal CYP3A23 by 1α, 25-dihydroxyvitamin D₃ in ratsYANG XU; IWANAGA, Kazunori; CHANGCHENG ZHOU et al.Biochemical pharmacology. 2006, Vol 72, Num 3, pp 385-392, issn 0006-2952, 8 p.Article

Pharmacogenetic determinants of human liver microsomal Alfentanil metabolism and the role of cytochrome P450 3A5KLEES, Theresa Mariero; SHEFFELS, Pamela; THUMMEL, Kenneth E et al.Anesthesiology (Philadelphia). 2005, Vol 102, Num 3, pp 550-556, issn 0003-3022, 7 p.Conference Paper

Role of itraconazole metabolites in CYP3A4 inhibitionISOHERRANEN, Nina; KUNZE, Kent L; ALLEN, Kyle E et al.Drug metabolism and disposition. 2004, Vol 32, Num 10, pp 1121-1131, issn 0090-9556, 11 p.Article

Genetic contribution to variable human CYP3A-mediated metabolismLAMBA, Jatinder K; LIN, Yvonne S; SCHUETZ, Erin G et al.Advanced drug delivery reviews. 2012, Vol 64, pp 256-269, issn 0169-409X, 14 p., SUPArticle

Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes : Implications for predicting clinical drug interactionsDIXIT, Vaishali; HARIPARSAD, Niresh; FANG LI et al.Drug metabolism and disposition. 2007, Vol 35, Num 10, pp 1853-1859, issn 0090-9556, 7 p.Article

Determination of free and total cortisol in plasma and urine by liquid chromatography-tandem mass spectrometryWEILI HUANG; KALHORN, Thomas F; BAILLIE, Mark et al.Therapeutic drug monitoring. 2007, Vol 29, Num 2, pp 215-224, issn 0163-4356, 10 p.Article

Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer RiskREDING, Kerryn W; LI, Christopher I; WEISS, Noel S et al.American journal of epidemiology. 2009, Vol 170, Num 10, pp 1241-1249, issn 0002-9262, 9 p.Article

Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney diseaseSMITH, Helen E; JONES, J. P; TOTAH, Rheem A et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 11, pp 943-953, issn 1744-6872, 11 p.Article

CYP3A activity in European American and Japanese men using midazolam as an in vivo probeTATEISHI, Tomonori; WATANABE, Minoru; NAKURA, Hironori et al.Clinical pharmacology and therapeutics. 2001, Vol 69, Num 5, pp 333-339, issn 0009-9236Article

Induction of CYP3A4 by 1α, 25-dihydroxyvitamin D₃ is human cell line-specific and is unlikely to involve pregnane X receptorSCHMIEDLIN-REN, Phyllissa; THUMMEL, Kenneth E; FISHER, Jeannine M et al.Drug metabolism and disposition. 2001, Vol 29, Num 11, pp 1446-1453, issn 0090-9556Article

Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or NelfinavirKIRBY, Brian J; COLLIER, Ann C; KHARASCH, Evan D et al.Drug metabolism and disposition. 2011, Vol 39, Num 6, pp 1070-1078, issn 0090-9556, 9 p.Article